Matinas BioPharma Holdings is a development stage biopharmaceutical company with a focus on identifying, developing and commercializing pharmaceutical products for the treatment of dyslipidemia and cardiovascular diseases. Its central focus is on developing MAT9001, a proprietary prescription-grade omega-3 fatty acid composition for the treatment of severe hypertriglyceridemia. Founded in 2011, the company is headquartered in Bedminster, New Jersey.  For more information, visit the company’s website at www.matinasbiopharma.com